During the past decade, significant advances in the treatment of neonatal respiratory distress syndrome (RDS) have been directly attributable to the emergence of surfactant replacement therapy. Using a variety of surfactant preparations, clinical trials have been accomplished in a number of centers on large numbers of infants. These clinical trials showed that there were applications of surfactant replacement both in the prevention mode, early in life, and in the rescue mode, once RDS is diagnosed. There were no evident adverse effects on the infants, and there was significant reduction in mortality and severity of disease in the treated infants. Currently, a large number of neonatal intensive care units are enrolling infants in treatment investigational drug (IND) protocols as defined by the Food and Drug Administration (FDA) while the new drug applications are pending. Surfactant replacement therapy has numerous implications for neonatal nurses and will be part of all neonatal nursing skills in the near future
Skip Nav Destination
Respiratory Care in Neonates| August 01 1990
On the Horizon: Surfactant Replacement Therapy
Michelle T. Renaud, RN, MS, LTC
From Darnall Army Hospital, Fort Hood, Texas.
Reprint requests to Michelle T. Renaud, RN, MS, LTC, 2702 Fishpond Lane, Killeen, TX 76541.
Search for other works by this author on:
AACN Adv Crit Care (1990) 1 (2): 422–426.
Michelle T. Renaud; On the Horizon: Surfactant Replacement Therapy. AACN Adv Crit Care 1 August 1990; 1 (2): 422–426. doi: https://doi.org/10.4037/15597768-1990-2021
Download citation file:
Don't already have an account? Register
AACN AccountSign In
Sign in via your InstitutionSign in via your Institution
Subscribe online and gain access to the entire archive.
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access